Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes Seven RNAi-Related Patent Applications: Apr 19, 2007

Premium
Title: Recombinant DNA Constructs and Methods for Controlling Gene Expression
 
Number: 20070083947, 20070083949, 20070083950, 20070083951, and 20070083952
 
Filed: Oct. 10, 2006
 
Inventor: Shihshieh Huang, Monsanto
 
The invention “provides molecular constructs and methods for use thereof, including constructs including heterologous miRNA recognition sites, constructs for gene suppression including a gene suppression element embedded within an intron flanked on one or on both sides by non-protein-coding sequence, constructs containing engineered miRNA or miRNA precursors, and constructs for suppression of production of mature microRNA in a cell,” according to the patent applications’ abstracts. “Also provided are transgenic plant cells, plants, and seeds containing such constructs, and methods for their use. The invention further provides transgenic plant cells, plants, and seeds containing recombinant DNA for the ligand-controlled expression of a target sequence, which may be endogenous or exogenous, [as well as] novel miRNAs and miRNA precursors from crop plants including maize and soy.”
 

 
Title: Methods for Inducing a Specific RNAi Activity in Cells and Nucleic Acids for Carrying Out Said Method
 
Number: 20070082864
 
Filed: Oct. 19, 2004 PCT Filed: Oct. 19, 2004
 
Inventor: Annick Harel-Bellan, French National Center for Scientific Research
 
The patent application, its abstract states, covers “a method for inducing activity of a specific RNAi into eukaryote cells in which the TAT protein and a nucleic acid coding for a nucleotide sequence comprising the sense and antisense sequences of an RNAi of interest are introduced, which sense and antisense sequences are separated by a separating nucleotide sequence coding for a sequence comprising at least the minimal TAR sequence recognized by the TAT protein, which transcribed separating sequence and the TAT protein form a complex that inhibits the activity of the RNAi of interest, and the activity of the RNAi is induced by withdrawing the TAT protein.”
 

 
Title: Multiple RNAi Expression Cassettes for Simultaneous Delivery of RNAi Agents Related to Heterozygotic Expression Patterns
 
Number: 20070081982
 
Filed: April 28, 2006
 
Inventor: Elisabeth Evertsz
 
The invention provides “compositions and methods suitable for expressing y-x multiple-RNAi agents against an allele or alleles of interest in cells, tissues, or organs of interest in vitro and in vivo so as to treat diseases,” the patent application’s abstract states.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.